January 22, 2007 / 12:43 PM / 12 years ago

Chelsea gains Orphan Drug status for Droxidopa

NEW YORK, Jan 22 (Reuters) - Chelsea Therapeutics International Ltd. CHTP.O said on Monday U.S. regulators granted orphan drug status to its experimental drug Droxidopa for treating a neurological disorder that can cause drops in blood pressure.

The Orphan Drug Act provides economic incentives to encourage development of drugs for diseases affecting fewer than 200,000 people in the United States.

Droxidopa is being developed as a treatment of symptomatic neurogenic orthostatic hypotension in certain patients. Chelsea plans to start a late-stage trial with Droxidopa during the second half of 2007.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below